Anterior urethral valve is a rare congenital anomaly that can cause obstructive uropathy. Herein, we report a case of an anterior urethral valve that led to the development of febrile urinary tract infection in a neonate.
Although transurethral resection of the prostate (TURP) is considered the standard surgical treatment for benign prostatic hyperplasia (BPH), Holmium laser enucleation of the prostate (HoLEP) is replacing TURP. We compared TURP with HoLEP with matching for prostate size.We retrospectively reviewed the medical charts of patients who underwent TURP and HoLEP performed by one surgeon at our institute. All patients were categorized into 3 groups on the basis of prostate size (group 1, <40 g; group 2, 40-79 g; and group 3, >80 g), and 45 patients were selected for each method.No major intraoperative complications were encountered. The mean resected tissue weight was 6.3, 18.3, and 28.0 g for groups 1, 2, and 3, respectively, for TURP and 8.7, 25.0, and 39.8 g, respectively, for HoLEP. The mean operation time was 51.8, 89.3, and 101.9 minutes for TURP and 83.6, 122.8, and 131.2 minutes for HoLEP in groups 1, 2, and 3, respectively. HoLEP had better resection efficacy than TURP for any size prostate, but there was no statistical difference between the methods. Both methods resulted in an immediate and significant improvement of International Prostate Symptom Score, peak urinary flow rates, and postvoid residual urine volume.HoLEP is effective for BPH treatment, regardless of prostate size, even in a small prostate. The perioperative morbidity of HoLEP is also comparable to that of TURP.
목적: 생후 3개월 이하 어린 영아에서 심각한 세균 감염 가운데 요로 감염이 가장 흔하다. 요추 천자는 발열의 평가 시 기본 검사에 포함되어 시행되는 경우가 많지만, 요로 감염 환자에서 수막염을 진단하기 위해 통상적으로 시행해야 하는 뚜렷한 지침은 없다. 이에 저자들은 어린 영아의 요로 감염에서 동반되는 세균성 수막염 및 무균성 뇌척수액 백혈구증가증의 유병률을 알아보기 위해 연구를 시행하였다. 방법: 2013년 1월부터 2016년 5월 사이 대구가톨릭병원 소아청소년과에서 요로 감염으로 입원하여 요추 천자를 시행한 생후 29일부터 99일 미만 영아 80명의 의무기록을 후향적으로 조사하였다. 분석 변수로는 대상 환자들의 인구학적 특징, 임상 증상, 검사 결과 및 치료를 조사하였고, 뇌척수액 백혈구 증가증을 보이는 군과 그렇지 않은 군을 비교하였다. 결과: 총 80명의 환자 가운데 34명(43%)에서 뇌척수액 백혈구증가증이 관찰되었다. 뇌척수액에서 세 균이 배양된 경우는 없었다. 뇌척수액 장바이러스 중합효소연쇄반응은 56명(70%)에서 시행하였고, 뇌척수액 백혈구증가증이 나타나지 않은 환자들 중 2명에서 양성이었다. 뇌척수액 백혈구증가증을 보이는 군과 그렇지 않는 군 간에 인구학적 특징, 검사실 소견, 영상검사, 치료 및 경과에 있어 양 군 간에 유의한 차이가 없었다. 결론: 신생아기 이후 어린 영아의 요로 감염에서 동반되는 뇌척수액 백혈구증가증은 흔하지만, 이의 원 인으로 세균이나 바이러스 감염에 의한 가능성은 아주 낮다. 전신 상태나 검사실 소견을 종합하여 요추 천자의 적응증을 개별적으로 평가하여 적용하는 것이 필요하다.
Purpose: Although transrectal ultrasound-guided prostate biopsy is useful for diagnosing prostate cancer, it is a painful procedure.There are many methods for providing pain relief and for treating discomfort during the procedure, but occasionally these are reported to be of limited use.We aimed to evaluate the value and safety of midazolam-induced anesthetic transrectal ultrasound-guided prostate biopsy.Materials and Methods: From August 2008 to December 2009, 104 male patients, who were examined with transrectal ultrasound-guided prostate 12-core biopsy, were randomly assigned to two groups.Group 1 (n=51) received ketorolac (Tarasyn Ⓡ ) 30 mg.Group 2 (n=53) was treated with midazolam (Dormicum Ⓡ ) 3 mg, which was increased to 5 mg if necessary.Immediately after the procedure, the patients were asked to rate their comfort level by using a 10-point visual analog self-assessment pain scale.Results: The pain scale in group 2 was significantly lower than that in group 1 (p<0.05).The patients assigned to group 2 experienced no side-effects from midazolam and were more satisfied than the patients in group 1 (p<0.05).Conclusions: Midazolam anesthesia relieves pain effectively, and the patient's satisfaction is better than with conventional transrectal ultrasound-guided prostate biopsy.Midazolam-induced anesthetic transrectal ultrasound-guided prostate biopsy is useful and safe.
Healthy aging is an important concern in an aging society. Although the causal relationship between hypogonadism and erectile dysfunction in elderly men remains unclear, many physicians have achieved positive results after implementing exogenous testosterone supplementation therapy in patients with normal or slightly low blood testosterone. The purpose of this study was to conduct a systematic review and meta-analysis on whether testosterone replacement therapy (TRT) could improve sexual function in the elderly, as reported recently.
This study aimed to assess the prognostic value of computed tomography (CT)-attenuation and 18F-fluorodeoxyglucose (FDG) uptake of periprostatic adipose tissue (PPAT) for predicting disease progression-free survival (DPFS) in patients with prostate cancer. Seventy-seven patients with prostate cancer who underwent staging FDG positron emission tomography (PET)/CT were retrospectively reviewed. CT-attenuation (HU) and FDG uptake (SUV) of PPAT were measured from the PET/CT images. The relationships between these PPAT parameters and clinical factors were assessed, and a Cox proportional hazard regression test was performed to evaluate the prognostic significance of PPAT HU and SUV. PPAT HU and SUV showed significant positive correlations with tumor stage and serum prostate-specific antigen level (PSA) (p < 0.05). Patients with high PPAT HU and SUV had significantly worse DPFS than those with low PPAT HU and SUV (p < 0.05). In multivariate analysis, PPAT SUV was a significant predictor of DPFS after adjusting for tumor stage, serum PSA, and tumor SUV (p = 0.003; hazard ratio, 1.50; 95% confidence interval, 1.15–1.96). CT-attenuation and FDG uptake of PPAT showed significant association with disease progression in patients with prostate cancer. These imaging findings may be evidence of the role of PPAT in prostate cancer progression.
The most important step in the differential diagnosis of mass lesions of the central skull base is to rule out malignant neoplasms. However, nonneoplastic lesions, such as infections or nonspecific inflammatory lesions of the skull base, can mimic malignant processes. In this study, the authors analyzed seven cases of nonneoplastic noninfectious mass-forming lesions involving the central skull base. In most cases, malignant processes were suspected at the initial phase of diagnostic work-up, but subsequent histologic examinations revealed that these lesions consisted of inflammatory cells and fibrosis without neoplastic cells. Common manifestations were pain and other neurological symptoms related to the involved anatomical sites. A variety of neurological dysfunctions of the cranial nerves not including the olfactory and spinal accessory nerves were observed. No patient developed separate lesions outside the head and neck region. After the pathologic diagnosis, most of the patients were treated with oral steroid therapy, with initial doses of prednisolone, 60 to 100 mg/d. It was difficult to relate responsiveness to steroid therapy with the histologic degree of sclerosis, fibrosis, or chronicity of the disease in these cases. Otolaryngologists should be aware of this disease when making treatment decisions for their patients with skull base lesions.